Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
YD Bio Limited ( (YDES) ) just unveiled an announcement.
On December 24, 2025, YD Bio Limited’s audit committee dismissed ARK Pro CPA & Co as the company’s independent registered public accounting firm and, effective the same day, appointed MaloneBailey, LLP as its new auditor for the fiscal year ending December 31, 2025. The company reported that between ARK Pro’s appointment on September 17, 2025, and its dismissal on December 24, 2025, there were no disagreements over accounting principles, financial statement disclosure, or audit scope that would qualify as reportable events under U.S. securities rules, and ARK Pro later confirmed its agreement with the company’s description of the circumstances in a letter dated January 6, 2026. YD Bio also stated that it had not consulted MaloneBailey on any such accounting or auditing matters during its two most recent financial years, suggesting the move reflects an auditor transition rather than a response to identified disputes, though stakeholders will likely watch for any implications for the company’s financial reporting and regulatory compliance.
The most recent analyst rating on (YDES) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on YD Bio Limited stock, see the YDES Stock Forecast page.
Spark’s Take on YDES Stock
According to Spark, TipRanks’ AI Analyst, YDES is a Neutral.
YD Bio Limited’s overall stock score is primarily impacted by its financial performance, which is hindered by negative profitability and cash flow issues. The technical analysis shows some short-term positive momentum, but the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on YDES stock, click here.
More about YD Bio Limited
YD Bio Limited is a Taiwan-based company headquartered in Taipei and listed in the United States as a foreign private issuer. The filing identifies it as subject to U.S. securities regulations but does not specify its precise industry, products, or services in the disclosed text.
Average Trading Volume: 73,940
Technical Sentiment Signal: Buy
Current Market Cap: $894.2M
Learn more about YDES stock on TipRanks’ Stock Analysis page.